Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

IVOSIDENIB vs JUXTAPID: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

IVOSIDENIB vs JUXTAPID: Safety Overview

Metric IVOSIDENIB JUXTAPID
Total FAERS Reports 1,695 179
Deaths Reported 121 2
Death Rate 7.1% 1.1%
Hospitalizations 505 13
Average Patient Age 67.9 yrs 58.0 yrs
% Female Patients 47.9% N/A
FDA Approval Date Jul 20, 2018 N/A
Manufacturer Servier Pharmaceutical LLC N/A
Route ORAL N/A
Marketing Status Prescription N/A